|
Objectives
To study the adaptive immune response to SARS-CoV
in patients at different stages of the disease (acute, convalescent,
recovered), with different degrees of severity (mild, requiring
intensive care unit, fatal) or existing underlying diseases (e.g.
diabetes). The humoral and the cellular components of the adaptive
immune response will be studied.
Description of work
From the cohort of patients followed in the Department
of Infectious Diseases at the PUMC hospital, serum and PBMC samples
have been sequentially collected and analyzed for T-cell subsets
and antibodies against SARS-CoV. Data and samples are available
for 100 patients in the acute phase, 65 up to the convalescent phase,
and 35 enrolled in a longterm follow-up. One major issue in the
scope of an active or passive immunization approach against SARS
disease is to know if the humoral response corresponds to neutralizing
antibodies or enhancing antibodies. Analysis of the cellular response
is also important to choose for a vaccine approach.
Humoral, cellular, cytokines profiles of the adaptive
immune response will be studied, including long-term (> 1 year)
persistence of neutralizing antibodies.
Deliverables
D44 Spectrum of immunological responses in SARS
patients in correlation with disease progression
D45 Baseline data in the scope of an active or
passive immunization approach.
Milestones and expected result
M0-M6: review of the existing
data
M6-M18: sample analysis after the first year of
follow-up
M12-M24: Synthesis and sharing of results with
experts in vaccinology
Expected results: better understanding of the adaptive immune response
to the SARS-CoV in humans to support active and passive immunization
approach to fight SARS.
|
